Human anti-PD-L1 peptide vaccine and its use
Synthetic PD-L1 peptides, incorporating specific epitopes and linkers, address the limitations of monoclonal antibodies by enhancing immune response and tumor suppression in cancer treatment.
JP7749543B2Active Publication Date: 2025-10-06OHIO STATE INNOVATION FOUND
5 Cites 0 Cited by
Patent Information
- Application Number
- JP2022517184
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-17
- Filing Date
- 2020-09-17
- Publication Date
- 2025-10-06
- Estimated Expiration
- 2040-09-17
AI Technical Summary
Technical Problem
Current cancer treatments using monoclonal antibodies targeting the PD-1/PD-L1 axis face challenges such as poor tissue penetration, limiting their efficacy in antagonizing signaling at tumor sites, and not all cancer patients respond to checkpoint blockade.
Method used
Development of synthetic PD-L1 peptides, including specific B-cell and T-helper epitopes, linked by a linker, to stimulate an immune response and potentially block the PD-1/PD-L1 interaction, either directly or through antibody generation.
Benefits of technology
The peptides effectively inhibit PD-1/PD-L1 signaling, demonstrating significant tumor growth suppression and improved treatment outcomes in cancer models, including increased immune response and potential for broader patient responsiveness.
✦ Generated by Eureka AI based on patent content.
Abstract
Disclosed are compositions related to synthetic PD-L1 peptides, chimeric PD-L1 peptides, anti-PD-L1 antibodies, and methods of using the peptides or antibodies to treat cancer, autoimmune diseases, and Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art